Eloxx Pharmaceuticals Inc ELOX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
-
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
-
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
-
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $13.12
- Day Range
- $12.80–14.00
- 52-Week Range
- $0.00–23.40
- Bid/Ask
- $7.00 / $14.00
- Shares Outstanding
- 4.04M
- Market Cap
- $43.98M
- Volume/Avg
- 27,605 / 38,928
Key Statistics
- Price/Earnings (Normalized)
- 3.93
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.eloxxpharma.com
Valuation
|
Metric
|
ELOX
|
|---|---|
Price/Earnings (Normalized) | 3.93 |
Price/Book Value | 1.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ELOX
Financial Strength
|
Metric
|
ELOX
|
|---|---|
Quick Ratio | 3.65 |
Current Ratio | 3.74 |
Interest Coverage | −35.53 |
Quick Ratio
ELOX
Profitability
|
Metric
|
ELOX
|
|---|---|
Return on Assets (Normalized) | −45.24% |
Return on Equity (Normalized) | −129.64% |
Return on Invested Capital (Normalized) | −122.80% |
Return on Assets
ELOX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|czG@vNB | LOCK|>bjC | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|vb^QnTz | LOCK|B?Tw | $83B | |||
| Moderna Inc
MRNA
| LOCK|r?&$%Q | LOCK|HD@ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|NxwYJL | LOCK|!LQ | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hM&L>$> | LOCK|Xg | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fWgSVN | LOCK|cxXRQ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|jZ@!X$W | LOCK|K%G^ | $28B | |||
| Incyte Corp
INCY
| LOCK|yS^<Tz | LOCK|>% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qLsr$q | LOCK|!Rv | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>&$fc! | LOCK|d^Y | $14B |
United States